

Research

Open Access

Cervical metastases of squamous cell carcinoma of the maxilla: a retrospective study of 9 years

Astrid LD Kruse* and Klaus W Grätz

Address: Department of Craniomaxillofacial and Oral Surgery, University of Zurich, Switzerland

Email: Astrid LD Kruse* - astridkruse@gmx.ch; Klaus W Grätz - klaus.graetz@zzmk.uzh.ch

* Corresponding author

Published: 20 July 2009

Received: 15 June 2009

Head & Neck Oncology 2009, 1:28 doi:10.1186/1758-3284-1-28

Accepted: 20 July 2009

This article is available from: <http://www.headandneckoncology.org/content/1/1/28>

© 2009 Kruse and Grätz; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose: Metastases of squamous cell carcinoma of the tongue and the mouth floor have been well studied. Concerning maxilla squamous cell carcinomas, however, only a few studies have been performed. The question is whether a prophylactic neck dissection should be performed in these tumors.

Patients and Material: In the Department of Craniomaxillofacial Surgery at the University Hospital of Zurich, 30 patients who had been treated for squamous cell carcinoma of the maxilla were examined retrospectively. Special attention was paid to direct and late metastasis, survival rate, and treatment.

Results: Of the 59 patients with upper jaw carcinomas over a 9-year period, only about half (30 patients) had a squamous cell carcinoma of the upper jaw. Of those patients, 27% had an upper lesion on the right side, 33% on the left. Of the 11 patients (36.7%) presenting positive lymph nodes, 4 patients had direct positive lymph nodes while 7 patients had later positive lymph nodes; and 71.4% of the late metastasis appeared during the first year.

Conclusion: Because of the 36.7% of patients presenting metastases in the cervical lymph nodes, elective neck treatment should be considered in cases even with a negative clinical examination.

Introduction

The estimated number of European patients with newly diagnosed cancers of the oral cavity and pharynx is 97,800 per year, and the estimated number of deaths because of these carcinomas is 40,100 in Europe per year. The worldwide incidence of oropharyngeal cancer is 8.3 cases per 100,000 [1]. Squamous cell carcinoma is the most common type of tumor among cancers in the oral cavity. These tumors metastasize, usually through the lymphatic system, to cervical lymph nodes in levels I and II [2,3]. Several studies have been done on the metastasis of

squamous cell carcinoma of the tongue/mouth floor and, in particular, on prophylactic neck dissection for tongue cancer [4]. It is well documented that patients with negative cervical lymph nodes have a good prognosis, but if lymph node metastasis occurs after excision of the primary tumor, the prognosis is poor.

Only a few investigations have been done into the metastasis of squamous cell carcinoma of the upper jaw. But it is striking that the incidence of cervical lymph node metastasis from cancer of the maxilla is significant [5].

Therefore, this retrospective study will present data concerning the proportion of metastasis in squamous cell carcinomas of the upper jaw.

Methods

Between January 1999 and July 2007, 59 patients with a malignant tumor of the upper jaw were referred to the Department of Cranio-Maxillofacial Surgery at the University Hospital of Zurich; of these, 30 patients had a squamous cell carcinoma of the upper jaw.

The female-male rate was 17:13, and the mean age of the first diagnosis was 73.1 years (in an age range of 32 – 91 years). All were staged by using the system of the International Union Against Cancer [6]. Pathohistological grading was also considered.

Results

A great number of the upper jaw tumors were found in the upper alveolar ridge (33% on the left, 27% on the right) (Fig. 1).

Out of 30 patients with squamous cell carcinoma of the upper jaw, 11 patients (36.7%) presented positive lymph nodes, with direct positive lymph nodes in 4 patients and later positive lymph nodes in 7 patients (Fig. 2).

The correlation between pathological T-status and the occurrence of metastatic lymph nodes is presented in fig

3. Of patients with positive lymph nodes, 5 were found in T1-tumors and 5 in T2-tumors (Fig. 3)

Indications for neck dissection were clinical involvement of the cervical lymph nodes and suspect cervical lymph nodes as a result of a Ct, MRI, or PET/Ct scan.

A supraomohyoidal neck dissection was performed on 2 patients because of suspect lymph nodes in a CT-scan, MRI, or PET, but the pathohistological exam revealed no positive lymph nodes in these cases. However, no metastasis has been revealed in these 2 patients up to now.

The most common pattern for positive cervical lymph nodes was in the present study at T1 G2 and T2 G2 status. In cases of late metastasis, 71.4% appeared during the first year (Fig. 4).

Of the 30 patients, 9 are dead of disease (Fig. 5). The 4 patients with direct positive lymph nodes are all alive, while 4 out of the 7 patients with late positive lymph nodes are deceased.

Discussion

Clinicopathologic factors associated with the development of cervical lymph node metastasis have been well studied for other locations like tongue, mouth floor, and cheek, in particular concerning tumor size (in tongue carcinoma ≥ 3 mm), tumor depth (≥ 4 mm in tongue carci-




Figure 1
Distribution of localizations in the upper jaw.




Figure 2
Distribution of patients with lymph node status.

noma), differentiation, mode of invasion, microvascular invasion, and histologic grade of malignancy [7-9]. The presence or absence of lymph node metastasis is one major prognostic factor for survival in patients with negative cervical lymph nodes [10]. A high incidence (20–30%) of cervical metastasis of cancer in the tongue/mouth floor has been well studied [7-9]. But very few studies have been performed concerning squamous cell carcinoma of the maxilla [5].

The results in the present study reveal that the higher the grading, the higher the risk of cervical metastasis. These results correlate with those of Sparano et al [8] (2004) for tongue cancer.

Simental et al. (2006) [5] found cervical metastasis from squamous cell carcinoma of the maxillary alveolus and

hard palate in 34.6% of patients. In the present study the portion of patients with cervical metastasis was similar (33.6%).

Haddadin et al. (1998) [4], Kligerman et al. (1994) [11] and Capote et al. (2006) [12] found that patients with clinical T1/T2 tongue cancer who underwent a synchronous neck dissection had an improved survival outcome. Also O'Brien et al. (2000) [13] found occult metastatic disease in 30% of patients, and Lim et al. (2006) [14-16] found it in 28%. Therefore, regarding the proportion of late cervical metastasis, the question arises whether an elective neck dissection should be provided in early-stage squamous cell carcinoma. Capote et al. (2006) [12] reported that in pT1N0 and pT2N0 oral squamous cell carcinoma, neck dissection therapy was a significant prognostic factor for recurrence and survival. Therefore tumor size, tumor depth, and differentiation should be taken into consideration for the planning of neck dissection for squamous cell carcinoma of the upper jaw. Also the mode of invasion plays an important role in therapy planning because in certain localizations like the palate, the tumor does not need to invade very deeply before reaching the bone. In the current study, it was surprising that only 6 patients revealed a T4 status.

Another problem that should be considered seems to be the detection of micrometastasis. The assessment of the status of cervical lymph nodes is difficult, and therefore a treatment of patients with a clinical stage N0 neck is controversial. In most studies the use of CT has an error rate ranging from 7.5 to 19% [17].




Figure 3
Distribution of tumor size and grading.




Figure 4
Time (months) elapsed till appearance of late lymph node metastasis.

In the late 1990s the positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG), a functional imaging methodology that provides information about tissue glucose metabolism, was applied. PET consequently a high FDG accumulation is manifested on PET images, but inflammation also reveals an increased FDG uptake and can lead to false-positive results. On the other hand, low tumor metabolic activity, the presence of small lesions, and hypoglycemia can lead to false-negative results [18]. Concerning cervical lymph nodes, Ng et al. (2005) [19] reported that sensitivity and specificity of PET images were 75% and 93%, respectively. Sigg et al. (2003) [20] reported a sensitivity of 93% and a specificity of 100%.

PET together with CT images showed a 15% increase in the accurate identification of nodal staging over using the PET images alone [21]. PET/CT seems to have a higher sensitivity and specificity for detecting lymph node metastasis [21,22]. In the last time the role of sentinel lymph node biopsies is discussed [23].

It is possible that prognostic markers – e.g., p53, CD44, cyclin D1 gene, and epidermal growth factor receptors for occult cervical lymph node metastasis that have been studied [24,25] – can help to optimize the treatment in patients with upper jaw cancer and occult metastatic lymph nodes.

The main limitation of this study was the low number of patients and the lack of carcinomas arising from the maxillary sinus. But considering the limitations of this study, multicenter studies should be performed in order to develop evidence-based protocols for treatment of squamous cell carcinomas of the maxilla.

Conclusion

Because of the 36.7% of the patients presenting metastases in the cervical lymph nodes from squamous cell car-




Figure 5
Distribution of deceased.

cinoma of the upper jaw, elective neck treatment should be considered even in cases with a negative clinical examination.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AK carried out the analysis of the patients' data and KWG participated in the design of the study and coordination.

Acknowledgements

We would like to thank Marius Bredell, Consultant, Department of Craniomaxillofacial Surgery, University Hospital Zurich, for critical reading.

References

1. Canto MT, Devesa SS: **Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998.** *Oral Oncol* 2002, **38(6)**:610-7.
2. Kowalski LP, Bagietto R, Lara JR, Santos RL, Tagawa EK, Santos IR: **Factors influencing contralateral lymph node metastasis from oral carcinoma.** *Head Neck* 1999, **21(2)**:104-10.
3. Pimenta Amaral TM, Da Silva Freire AR, Carvalho AL, Pinto CA, Kowalski LP: **Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth.** *Oral Oncol* 2004, **40(8)**:780-6.
4. Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG: **Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection.** *Head Neck* 1999, **21(6)**:517-25.
5. Simental AA Jr, Johnson JT, Myers EN: **Cervical metastasis from squamous cell carcinoma of the maxillary alveolus and hard palate.** *Laryngoscope* 2006, **116(9)**:1682-4.
6. International Union Against Cancer: *TNM classification of malignant tumors* 4th edition. Berlin: Springer-Verlag; 1987.
7. Kurokawa H, Yamashita Y, Takeda S, Zhang M, Fukuyama H, Takahashi T: **Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue.** *Head Neck* 2002, **24(8)**:731-6.
8. Sparano A, Weinstein G, Chalian A, Yodul M, Weber R: **Multivariate predictors of occult neck metastasis in early oral tongue cancer.** *Otolaryngol Head Neck Surg* 2004, **131(4)**:472-6.
9. Wallwork BD, Anderson SR, Coman VVB: **Squamous cell carcinoma of the floor of the mouth: tumour thickness and the rate of cervical metastasis.** *ANZ J Surg* 2007, **77(9)**:761-4.

10. Hiratsuka H, Miyakawa A, Nakamori K, Kido Y, Sunakawa H, Kohama G: **Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity.** *Cancer* 1997, **80(3)**:351-6.
11. Kligerman J, Lima RA, Soares JR, Prado L, Dias FL, Freitas EQ, Olivatto LO: **Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity.** *Am J Surg* 1994, **168(5)**:391-4.
12. Capote A, Escorial V, Muñoz-Guerra MF, Rodríguez-Campo FJ, Gamallo C, Naval L: **Elective neck dissection in early-stage oral squamous cell carcinoma – does it influence recurrence and survival?** *Head Neck* 2007, **29(1)**:3-11.
13. O'Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM: **The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx.** *Arch Otolaryngol Head Neck Surg* 2000, **126(3)**:360-5.
14. Lim YC, Koo BS, Lee JS, Lim JY, Choi EC: **Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck.** *Laryngoscope* 2006, **116(7)**:1148-52.
15. Lim YC, Lee JS, Koo BS, Kim SH, Kim YH, Choi EC: **Treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation.** *Laryngoscope* 2006, **116(3)**:461-5.
16. Lim YC, Koo BS, Lee JS, Lim JY, Choi EC: **Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck.** *Laryngoscope* 2006, **116(7)**:1148-52.
17. Brekel MW van den, Stel HV, Castelijns JA, Nauta JJ, Waal I van der, Valk J, Meyer CJ, Snow GB: **Cervical lymph node metastasis: assessment of radiologic criteria.** *Radiology* 1990, **177(2)**:379-84.
18. Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, Murakami D, Tomiguchi S, Oya N, Katsuragawa S, Yamashita Y: **Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.** *Int J Radiat Oncol Biol Phys* 2007, **68(2)**:377-82. Epub 2007 Feb 22.
19. Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF: **18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.** *J Nucl Med* 2005, **46(7)**:1136-43.
20. Sigg MB, Steinert H, Grätz K, Hugenin P, Stoeckli S, Eyrich GK: **Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.** *J Oral Maxillofac Surg* 2003, **61(9)**:1022-9.
21. Jeong HS, Baek CH, Son YI, Ki Chung M, Kyung Lee D, Young Choi J, Kim BT, Kim HJ: **Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma.** *Head Neck* 2007, **29(3)**:203-10.
22. Wild D, Eyrich GK, Ciernik IF, Stoeckli SJ, Schuknecht B, Goerres GW: **In-line (18F)-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.** *J Craniomaxillofac Surg* 2006, **34(1)**:9-16. Epub 2005 Dec 15.
23. Devaney KO, Rinaldo A, Rodrigo JP, Ferlito A: **Sentinel node biopsy and head and neck tumors – where do we stand today?** *Head Neck* 2006, **28(12)**:1122-31.
24. Ferlito A, Rinaldo A, Silver CE, Shah JP, Suárez C, Medina JE, Kowalski LP, Johnson JT, Strome M, Rodrigo JP, Werner JA, Takes RP, Towpik E, Robbins KT, Leemans CR, Herranz J, Gavilán J, Shaha AR, Wei WJ: **Neck dissection: then and now.** *Auris Nasus Larynx* 2006, **33(4)**:365-74. Epub 2006 Aug 4.
25. Elsheikh MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A: **Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma.** *Head Neck* 2006, **28(9)**:842-9.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

